Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Abstract The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenced by genetic, epigenetic, and environmental factors. iPSCs offer a distinctive platform for investigating the origin of cancer, paving the way for novel approaches to cancer treatment, drug testing, and tailored medical interventions. This review article will provide an overview of the science behind iPSCs, the current limitations and challenges in iPSC-based cancer therapy, the ethical and social implications, and the comparative analysis with other stem cell types for cancer treatment. The article will also discuss the applications of iPSCs in tumorigenesis, the future of iPSCs in tumorigenesis research, and highlight successful case studies utilizing iPSCs in tumorigenesis research. The conclusion will summarize the advancements made in iPSC-based tumorigenesis research and the importance of continued investment in iPSC research to unlock the full potential of these cells..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Molecular cancer - 22(2023), 1 vom: 28. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chehelgerdi, Matin [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Immunotherapies |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12943-023-01873-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053897757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053897757 | ||
| 003 | DE-627 | ||
| 005 | 20231129064645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231129s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12943-023-01873-0 |2 doi | |
| 035 | |a (DE-627)SPR053897757 | ||
| 035 | |a (SPR)s12943-023-01873-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chehelgerdi, Matin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenced by genetic, epigenetic, and environmental factors. iPSCs offer a distinctive platform for investigating the origin of cancer, paving the way for novel approaches to cancer treatment, drug testing, and tailored medical interventions. This review article will provide an overview of the science behind iPSCs, the current limitations and challenges in iPSC-based cancer therapy, the ethical and social implications, and the comparative analysis with other stem cell types for cancer treatment. The article will also discuss the applications of iPSCs in tumorigenesis, the future of iPSCs in tumorigenesis research, and highlight successful case studies utilizing iPSCs in tumorigenesis research. The conclusion will summarize the advancements made in iPSC-based tumorigenesis research and the importance of continued investment in iPSC research to unlock the full potential of these cells. | ||
| 650 | 4 | |a Induced pluripotent stem cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumorigenesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Regenerative medicine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Personalized medicine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Behdarvand Dehkordi, Fereshteh |4 aut | |
| 700 | 1 | |a Chehelgerdi, Mohammad |0 (orcid)0000-0002-3483-9424 |4 aut | |
| 700 | 1 | |a Kabiri, Hamidreza |4 aut | |
| 700 | 1 | |a Salehian-Dehkordi, Hosein |4 aut | |
| 700 | 1 | |a Abdolvand, Mohammad |4 aut | |
| 700 | 1 | |a Salmanizadeh, Sharareh |4 aut | |
| 700 | 1 | |a Rashidi, Mohsen |4 aut | |
| 700 | 1 | |a Niazmand, Anoosha |4 aut | |
| 700 | 1 | |a Ahmadi, Saba |4 aut | |
| 700 | 1 | |a Feizbakhshan, Sara |4 aut | |
| 700 | 1 | |a Kabiri, Saber |4 aut | |
| 700 | 1 | |a Vatandoost, Nasimeh |4 aut | |
| 700 | 1 | |a Ranjbarnejad, Tayebeh |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer |d London : Biomed Central, 2002 |g 22(2023), 1 vom: 28. Nov. |w (DE-627)SPR028851633 |w (DE-600)2091373-4 |x 1476-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:28 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12943-023-01873-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 28 |c 11 | ||